Michigan Lawmaker warns federal proposal could reclassify cannabis seeds
✦ New CED Clinical Relevance #47 Clinical Context Background information relevant to the evolving cannabis medicine landscape. PolicyHempTHCResearchIndustrySafetyDosing Why This Matters If cannabis seeds are reclassified as controlled substances…
German Advocates: Cannabis Flowers Are Necessary For Medical Care
✦ New CED Clinical Relevance #52 Clinical Context Background information relevant to the evolving cannabis medicine landscape. PolicyPainMental HealthAnxietyNeurologySafetyResearch Why This Matters Clinicians in Germany need to understand this…
Only 1 in 3 Older Adults Screened for Cannabis, Drug Use
✦ New CED Clinical Relevance #52 Clinical Context Background information relevant to the evolving cannabis medicine landscape. AgingResearchSafetyMental HealthPolicyPainAnxiety Why This Matters Clinicians may be missing substance use disorders in…
Maine warns of unsafe pesticides in some cannabis vapes
✦ New CED Clinical Relevance #67 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. PolicySafetyTHCIndustryHempResearchDosing Why This Matters Clinicians should be aware that pesticide-contaminated…
Q&A: What does science say about plants as medicine?
✦ New CED Clinical Relevance #67 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ResearchCBDTHCSafetyDosingHempPolicy Why This Matters Clinicians need evidence-based guidance on cannabinoid pharmacology…
GLP-1 Weight Loss Drugs: Male Fertility Safety Evidence
GLP-1 receptor agonist male fertility safety is supported by current evidence showing no adverse effects on reproductive function. Studies indicate these drugs may improve fertility outcomes through metabolic benefits. This reassures clinicians and…
GLP-1 Drugs: Cardiovascular Outcomes Clinical Evidence
GLP-1 receptor agonists cardiovascular outcomes show benefits beyond glycemic control and weight loss. Clinical evidence supports their role in reducing cardiovascular risk. These drugs also contribute to metabolic health and muscle mass preservation.
Semaglutide vs Tirzepatide: FDA Safety Data Analysis
This article reviews the semaglutide tirzepatide safety comparison based on FDA data. Both GLP-1 receptor agonists have similar adverse event profiles, primarily gastrointestinal side effects. Understanding this safety comparison helps clinicians…
CB2 Agonists and the Blood-Brain Barrier: Why This Preclinical Signal Is Still Early
CB2 receptor agonists neuroinflammation research shows promising anti-inflammatory effects on the blood-brain barrier in preclinical models. This early signal highlights mechanistic insights but lacks human clinical evidence. Further studies are needed…
GLP-1 Semaglutide: Compounded vs Wegovy Options
This article examines compounded semaglutide vs Wegovy options for GLP-1 therapy in weight management. It highlights differences in FDA approval, cost, and clinical safety. Understanding these options helps prescribers guide patients effectively.